Sahar Abdollahi Jahdi1, Parviz Parvin1, Solaleh Seyedi1, Saeid Jelvani2, Mohammad Reza Razzaghi3. 1. Physics Department, Amirkabir University of Technology, Tehran, Iran. 2. Photonics and Quantum Technologies Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran. 3. Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract
Introduction: Spectroscopic properties of Xeloda chemodrug have been studied over varying concentrations ranging between 0.001 and 10 mg/mL, using laser-induced fluorescence (LIF) spectroscopy. The alternative photoluminescence (PL) and near infrared (NIR) measurements are carried out to authenticate the obtained results by the LIF method. Methods: The XeCl laser as the excitation coherent source with 160 mJ/pulse at 308 nm is employed for LIF measurements of the fluorophore of interest in the modular spectroscopic set-up. Results: Xeloda as a significant chemodrug acts as a notable fluorophore. LIF, PL and NIR spectroscopy techniques are employed to investigate the spectral properties of the chemodrug in terms of concentration. The maximum LIF peak intensity of Xeloda is achieved at λmax=410.5 nm and the characteristic concentration of CP1=0.05 mg/mL. PL signals are in good agreement with the data given by the LIF measurements. The characteristic NIR spectra of Xeloda as solid evidence of chemical bonding formation attest to fluorescence quenching at the fluorophore concentration of ~ 0.2 mg/ mL. Besides, the spectral shift of fluorescence signals which is obtained in terms of fluorophore concentration- demonstrating as a diagnostic marker for the purpose of optimized chemotherapy. Conclusion: Xeloda exhibits outstanding fluorescence properties over the allowable concentration in human serum (Cmax). These characteristics could benefit potential advantage of simultaneous laser-based imaging of cell-chemodrug interaction over in-vivo studies.
Introduction: Spectroscopic properties of Xeloda chemodrug have been studied over varying concentrations ranging between 0.001 and 10 mg/mL, using laser-induced fluorescence (LIF) spectroscopy. The alternative photoluminescence (PL) and near infrared (NIR) measurements are carried out to authenticate the obtained results by the LIF method. Methods: The XeCl laser as the excitation coherent source with 160 mJ/pulse at 308 nm is employed for LIF measurements of the fluorophore of interest in the modular spectroscopic set-up. Results: Xeloda as a significant chemodrug acts as a notable fluorophore. LIF, PL and NIR spectroscopy techniques are employed to investigate the spectral properties of the chemodrug in terms of concentration. The maximum LIF peak intensity of Xeloda is achieved at λmax=410.5 nm and the characteristic concentration of CP1=0.05 mg/mL. PL signals are in good agreement with the data given by the LIF measurements. The characteristic NIR spectra of Xeloda as solid evidence of chemical bonding formation attest to fluorescence quenching at the fluorophore concentration of ~ 0.2 mg/ mL. Besides, the spectral shift of fluorescence signals which is obtained in terms of fluorophore concentration- demonstrating as a diagnostic marker for the purpose of optimized chemotherapy. Conclusion: Xeloda exhibits outstanding fluorescence properties over the allowable concentration in human serum (Cmax). These characteristics could benefit potential advantage of simultaneous laser-based imaging of cell-chemodrug interaction over in-vivo studies.
Authors: B Reigner; J Verweij; L Dirix; J Cassidy; C Twelves; D Allman; E Weidekamm; B Roos; L Banken; M Utoh; B Osterwalder Journal: Clin Cancer Res Date: 1998-04 Impact factor: 12.531
Authors: S Seyedi; P Parvin; A Jafargholi; S Jelvani; M Shahabi; M Shahbazi; P Mohammadimatin; A Moafi Journal: Spectrochim Acta A Mol Biomol Spectrosc Date: 2020-05-14 Impact factor: 4.098
Authors: Joan Albanell; Clara Montagut; Eileen T Jones; Linda Pronk; Begoña Mellado; Janette Beech; Pere Gascon; Gerhard Zugmaier; Michael Brewster; Mark P Saunders; Juan W Valle Journal: Clin Cancer Res Date: 2008-05-01 Impact factor: 12.531
Authors: Francesco Di Costanzo; Roberto Ravasio; Alberto Sobrero; Oscar Bertetto; Orazio Vinante; Gabriele Luppi; Roberto Labianca; Dino Amadori; Carlo Barone; Marco Carlo Merlano; Flavia Longo; Giovanni Mansueto; Lorenzo Antonuzzo; Silvia Gasperoni Journal: Clin Drug Investig Date: 2008 Impact factor: 2.859